Alkermes plc
ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and preventionā¦ read more
Healthcare
Biotechnology
33 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$29.05
Price+2.80%
$0.79
1Y
Price
Market Cap
$4.796b
Mid
Price/Earnings 3y Avg5y Avg
14x
Premium
Premium
Financials Overview
Key metrics over the past few years+29.2%
EBITDA Margin+22.9%
Net Profit Margin+34.8%
Free Cash Flow MarginRevenue
$1.505b
-9.3%
1y CAGR+11.7%
3y CAGR+12.0%
5y CAGREarnings
$348.446m
-18.8%
1y CAGR+25.8%
3y CAGR+33.5%
5y CAGREPS
$2.07
-20.0%
1y CAGR+24.4%
3y CAGR+32.6%
5y CAGRBook Value
$1.625b
$2.253b
Assets$628.225m
Liabilities$72.678m
DebtDebt to Assets
3.2%
1.2x
Debt to EBITDAFree Cash Flow
$479.842m
-7.4%
1y CAGR+673.9%
3y CAGR+525.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company